| Name | Title | Contact Details |
|---|---|---|
Michael Whelihan |
Director, Research & Development | Profile |
Heritage Living Ctr is a Ashland, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedSignals is a Morrisville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EKOS Corporation was founded in 1995 with the vision that ultrasound could accelerate the delivery of drugs to benefit patients with a variety of diseases and conditions. Today, EKOS is the world leader in providing ultrasound-assisted, fluid infusion
Cenduit is the leading IRT systems specialist in the world, with rapid study startup software, clinical supply chain intelligence, clinical operations know-how and customer-centric CORE teams making sure your study starts quickly and runs smoothly. Other IRT-driven services include patient randomization and trial supply management (RTSM), integration, patient engagement and materials forecasting. We have over 500 experts worldwide in the US, UK, Switzerland, India, Japan and China, with clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. Let Cenduit`s experts ensure that your study needs are met on time and within budget.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.